MedPath

Tagged News

Subcutaneous EEG Device Demonstrates Superior Seizure Detection in Treatment-Resistant Epilepsy Study

AI
  • A landmark study published in Epilepsia shows that a subcutaneous EEG device accurately detected seizures in patients with treatment-resistant epilepsy over 15 months of home monitoring.
  • The AI-powered implantable device captured 754 seizures across nearly 72,000 hours of real-world data, revealing that patients only correctly recorded 48% of their episodes in traditional seizure diaries.
  • The coin-sized device, placed under the scalp behind the ear, was well-tolerated by participants and could transform epilepsy treatment by providing objective seizure data to clinicians.
  • Results demonstrate the potential for this technology to replace unreliable patient-reported seizure tracking, particularly benefiting the one-third of epilepsy patients who have treatment-resistant disease.

Almirall and Absci Expand AI Drug Discovery Partnership with Second Dermatology Target

AIDrug DiscoveryMonoclonal Antibody
  • Almirall and Absci have expanded their AI drug discovery collaboration to include a second dermatology target following successful delivery of AI-designed antibody leads against a difficult-to-drug target.
  • The collaboration combines Absci's Integrated Drug Creation™ platform with Almirall's dermatology expertise to develop novel therapeutics for chronic and debilitating skin diseases.
  • Under the expanded partnership terms, Absci is eligible to receive up to approximately $650 million in milestone payments across both programs, plus royalties on potential product sales.
  • The partnership demonstrates the potential of AI de novo drug design to unlock novel biology where traditional drug discovery approaches have previously failed.

Chai Discovery Raises $70M Series A to Revolutionize Antibody Design with AI Platform Achieving 20% Hit Rate

AIDrug DiscoveryMonoclonal Antibody
  • Chai Discovery secured $70 million in Series A funding led by Menlo Ventures, bringing total funding to $100 million to advance AI-driven drug discovery.
  • The company's breakthrough Chai-2 platform achieves a near-20% hit rate in fully de novo antibody design, dramatically outperforming traditional methods and previous computational approaches.
  • Former Pfizer Chief Scientific Officer Mikael Dolsten joins the board, bringing experience from advancing 150 molecules into clinical trials and delivering 36 approved medicines.
  • The AI platform can generate successful antibody binders from scratch using only target antigen and epitope information, potentially transforming therapeutic development timelines.

ImmunoPrecise Antibodies Divests Netherlands Operations for $12M to Focus on AI-Driven Drug Discovery Platform

AIDrug Discovery
  • ImmunoPrecise Antibodies sold its Netherlands subsidiary to AVS Bio for $12 million USD, generating $11.7 million in net proceeds to strengthen its balance sheet.
  • The divestiture allows IPA to concentrate resources on its AI-based LENSai™ platform, which uses HYFT® multi-omics technology to accelerate biologics discovery.
  • The strategic move reflects IPA's shift toward Software as a Service (SaaS) solutions that unify complex biological data for more efficient drug development processes.

Porosome Therapeutics Reports Breakthrough Alzheimer's Platform with FDA-Validated Organoid Studies and AI-Designed Therapeutics

AIDrug Discovery
  • Porosome Therapeutics announced key advancements in its first-in-class, disease-modifying neurological platform that targets the root causes of Alzheimer's disease rather than just symptom management.
  • The company demonstrated significant reduction of Tau protein levels, an FDA-approved biomarker, and rapid reversal of Alzheimer's pathology within two weeks using FDA-validated human brain organoid models.
  • Three distinct therapeutic classes have been identified including small molecules, biologics, and AI-designed decoy peptides that neutralize toxic beta amyloid peptides.
  • The company is actively exploring the FDA's accelerated approval pathway based on quantifiable, biomarker-driven improvements in their studies.

Merck's Ifinatamab Deruxtecan Receives FDA Breakthrough Designation for Small Cell Lung Cancer

AIDrug DiscoveryOncology
  • Merck and Daiichi Sankyo's ifinatamab deruxtecan received FDA Breakthrough Therapy Designation for extensive-stage small cell lung cancer patients who progressed after platinum-based chemotherapy.
  • The B7-H3 directed antibody-drug conjugate represents the first BTD for the collaboration and addresses significant unmet medical needs in SCLC, a disease with limited therapeutic options.
  • The designation follows positive Phase 2 IDeate-Lung01 trial data and accelerates regulatory pathways, potentially expediting approval timelines for this innovative cancer therapy.
  • Merck also announced a strategic AI partnership with Turbine to create virtual tumor models for hard-to-treat cancers, leveraging Simulated Cells™ technology to accelerate drug discovery.

SOPHiA GENETICS and AstraZeneca Expand AI Partnership to Optimize Breast Cancer Treatment Outcomes

AIReal World Evidence
  • SOPHiA GENETICS and AstraZeneca announced a multi-year collaboration expansion to leverage multimodal AI Factories for generating evidence on breast cancer therapy efficacy and real-world impact.
  • The partnership will utilize AI to analyze genomics, imaging, and clinical data to develop predictive models aimed at optimizing treatment outcomes for breast cancer patients.
  • The collaboration will focus on real-world evidence generation across Europe and North America to identify key drivers of treatment efficacy and enhance clinical decision-making.
  • AstraZeneca will integrate SOPHiA GENETICS's AI platform to augment their frontier AI solutions across oncology clinical development and improve understanding of disease biology.

Yatiri Bio Acquires NGeneBioAI to Strengthen AI-Powered Proteomics Platform for Precision Medicine

AIPrecision Medicine
  • Yatiri Bio has successfully acquired NGeneBioAI, a San Diego-based company specializing in plasma proteomics and AI-powered diagnostics, to strengthen its position in biomarker discovery and translational drug development.
  • The acquisition expands Yatiri Bio's operational capabilities by integrating CLIA- and CAP-certified laboratory infrastructure and enhancing its AI-proteomics platform that uses deep learning to map disease biology.
  • The expanded platform will support biomarker-driven programs across oncology, immunology, and neurodegeneration while strengthening partnerships with biopharma companies seeking companion diagnostics.
  • Yatiri Bio's platform uses deep neural networks to integrate proprietary proteomics, clinical metadata, and functional testing to identify responsive patient populations for clinical candidates.

Taconic and Cyagen Form Strategic Partnership to Expand Access to 16,000+ Genetically Engineered Mouse Models

AIDrug Discovery
  • Taconic Biosciences and Cyagen Biosciences announced a strategic partnership to provide preclinical researchers with streamlined access to Cyagen's library of over 16,000 genetically engineered mouse models.
  • Taconic will serve as the exclusive distributor of Cyagen's animal model library in North America and Europe, combining AI-generated models with world-class production services.
  • The collaboration expands Taconic's existing library from 4,500 to over 20,500 mouse models, including knockout, conditional knockout, and Cre-recombinase expressing models for disease research.
  • The partnership aims to accelerate drug discovery across multiple therapeutic areas including neurodegeneration, rare diseases, immuno-oncology, and metabolic disorders.

OneMedNet Expands Real-World Data Network by 25%, Adding 5 Billion Administrative Records

AIRare Disease
  • OneMedNet Corporation announced a greater than 25% expansion of its proprietary iRWD™ network, adding over 5 billion administrative records to support health economics research and social determinants of health insights.
  • The expanded network now encompasses 1,750+ healthcare system and provider partner sites, covering 34 million patients and 136 million clinical exams across rare diseases, oncology, and cardiology.
  • The expansion positions OneMedNet for significant revenue growth through increased data licensing and enterprise partnerships in the $60 billion real-world evidence industry.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.